Heidelberg‑based Exciva closed a €51 million ($59 million) Series B to advance its clinical candidate into phase 2 testing for agitation in Alzheimer’s disease. The financing will fund a mid‑stage program addressing a common behavioral symptom with high unmet medical need, positioning Exciva to deliver randomized controlled data to support regulatory pathways and partnering discussions. The raise underscores investor appetite for symptomatic Alzheimer’s therapies that can improve patient quality of life and reduce caregiver burden, and it provides Exciva runway to execute a phase‑2 protocol expected to generate proof‑of‑concept safety and efficacy readouts. Why it matters: targeted symptom management in Alzheimer’s remains commercially and clinically important; this financing moves a mid‑stage candidate closer to pivotal development and potential partner interest.